Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma. Toripalimab...
9 KB (603 words) - 00:28, 30 September 2024
FDA in March 2023 for the treatment of Merkel cell carcinoma (MCC). Toripalimab (Loqtorzi) is a humanized IgG4 monoclonal antibody against PD-1 approved...
35 KB (3,450 words) - 03:38, 30 September 2024
cells that may have remained. The Food and Drug Administration approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine...
29 KB (3,186 words) - 10:47, 3 June 2024
2015. "Toripalimab - Shanghai Junshi Biosciences - AdisInsight". adisinsight.springer.com. Retrieved 2019-08-25. Keam, S.J. (2019). "Toripalimab: First...
39 KB (4,995 words) - 13:28, 2 November 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
80 KB (7,412 words) - 02:30, 16 October 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
46 KB (4,813 words) - 05:06, 15 October 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
37 KB (3,213 words) - 00:29, 30 September 2024
doi:10.1007/s40265-021-01614-x. PMID 34661865. "Disitamab vedotin plus toripalimab shows promise for advanced urothelial carcinoma". Urology Times. June...
4 KB (190 words) - 14:36, 15 August 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
13 KB (1,060 words) - 00:29, 30 September 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
9 KB (460 words) - 00:28, 30 September 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
28 KB (2,721 words) - 04:14, 1 October 2024
govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zolbetuximab...
12 KB (821 words) - 02:57, 12 October 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
15 KB (1,447 words) - 00:31, 30 September 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
43 KB (4,183 words) - 04:17, 1 October 2024
protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab...
2 KB (160 words) - 21:52, 16 October 2024
L01FF10 Retifanlimab L01FF11 Sugemalimab L01FF12 Serplulimab L01FF13 Toripalimab L01FG01 Bevacizumab L01FG02 Ramucirumab L01FX01 Edrecolomab L01FX02 Gemtuzumab...
12 KB (877 words) - 15:36, 25 January 2024
govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zolbetuximab...
12 KB (758 words) - 23:46, 14 March 2024